Moderate Risk QT Prolonging Agents

This page covers all Moderate Risk QT Prolonging Agents drugs tracked by Drug Landscape: marketed products and active clinical-stage compounds, targeting 3-phosphoinositide-dependent protein kinase 1, Troponin C, slow skeletal and cardiac muscles.

Targets

3-phosphoinositide-dependent protein kinase 1 · Troponin C, slow skeletal and cardiac muscles

Marketed (2)

• Sunitinib Malate · Pfizer · Oncology
  Sunitinib is a small molecule that inhibits multiple receptor tyrosine kinases, including PDGFRα, PDGFRβ, VEGFR1, VEGFR2, VEGFR3, KIT, FLT3, CSF-1R, and RET.
• Sutent · Pfizer · Oncology
  Sunitinib is a small-molecule, multi-targeted receptor tyrosine kinase inhibitor that inhibits PDGFRα, PDGFRβ, VEGFR1, VEGFR2, and KIT.

Phase 3 pipeline (1)

• Simdax · Cardiovascular
  Simdax works by binding to troponin C, increasing calcium sensitivity in cardiac muscle cells, allowing for improved heart function without increasing oxygen demand.